Fate Therapeutics, Inc. beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.28 | $-0.25 | +10.7% | Beat |
| Q12026 FY2026 | $-0.29 | $-0.26 | +10.3% | Beat |
| Q42025 FY2025 | $-0.27 | $-0.27 | +0.0% | Beat |
Back to FATE overview · FATE holders · FATE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.